TA-106

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTA-106
Drug Alias Nameanti-factor B FAb (Alexion)FAb antibody fragment (Taligen Therapeutics)TA-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsInflammationThrombotic MicroangiopathiesHematologic Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlexion Cambridge Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlexion Cambridge CorpAlexion Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInflammationThrombotic MicroangiopathiesHematologic Diseases +[5] 

Other Information

ATC CodeN/A
Related LinksN/A